In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > BUSINESS
BUSINESS
- Major Japanese Drug Makers Strengthen Vaccine Business, Eyeing Global Operations
October 30, 2012
- Shionogi to Take Part in GSK-Pfizer JV, Realigns Strategy in HIV Field
October 30, 2012
- DSP, Takeda Submit Application for Antipsychotic Lurasidone in Europe
October 30, 2012
- Nihon Chouzai to Make Choseido its Subsidiary to Strengthen Generic Products Supply Capacity
October 30, 2012
- Chugai to License SGLT-2 Inhibitor to Kowa, Sanofi
October 29, 2012
- Kyowa Kirin: Pharmaceutical Sales Up 8.4%, but Domestic Sales Down in January to September Period
October 29, 2012
- Nippon Chemiphar Revises 1st Half Business Forecast Upward, Full Year Forecast Unchanged
October 29, 2012
- MTPC to Launch Quadruple Vaccine TETRABIK on October 31 with 50 Vaccine Specialized MRs
October 29, 2012
- Janssen’s New MR Training System Aims to Produce “Consulting MRs”
October 29, 2012
- Everlth President Hasegawa Sends Out Information to World on Activities of Pharmaceutical Wholesalers at Time of Great East Japan Earthquake
October 26, 2012
- Takeda Starts Detailing Activities through M3’s “Tenohira MR-kun” on iPads
October 26, 2012
- AnGes MG Inks Definitive Deal to Grant Exclusive US Marketing Rights for Collategene to MTPC
October 25, 2012
- Kyowa Kirin to Construct Biopharmaceutical API Manufacturing Facility
October 25, 2012
- Ono Ties Up with Domain Therapeutics of France for GPCR-Based Drug Discovery
October 25, 2012
- ZOLL Medical Acquired by Asahi Kasei Last Year Establishes Japanese Subsidiary
October 25, 2012
- Fujifilm, Kyowa Kirin to Develop Avastin Biosimilar
October 25, 2012
- “Changing Way of Thinking Necessary among Industry, Government, Academia for Promotion of Drug Discovery”: AZ Chairman Kato
October 25, 2012
- Santen Going on Offensive in Growth Fields in Ophthalmology
October 24, 2012
- More Products, Fewer Facilities Per MR: Novartis Introduces New Marketing System
October 24, 2012
- Kaken Pharmaceutical Files NDA for Efinaconazole, 1st Topical Drug for Onychomycosis in Japan
October 24, 2012
ページ
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…